Results 1 to 10 of about 382,620 (401)

Software Tools and Approaches for Compound Identification of LC-MS/MS Data in Metabolomics. [PDF]

Metabolites, 2018
The annotation of small molecules remains a major challenge in untargeted mass spectrometry-based metabolomics. We here critically discuss structured elucidation approaches and software that are designed to help during the annotation of unknown compounds.
Blaženović, Ivana, Fiehn, Oliver, Ji, Jian, Kind, Tobias   +3 more
core   +4 more sources

MetaboLights: open data repository for metabolomics

Nucleic Acids Research, 2023
MetaboLights is a global database for metabolomics studies including the raw experimental data and the associated metadata. The database is cross-species and cross-technique and covers metabolite structures and their reference spectra as well as their ...
Ozgur Yurekten, Thomas Payne, Noemi Tejera, Felix Xavier Amaladoss, Callum Martin, Mark Williams, Claire O’Donovan   +6 more
semanticscholar   +1 more source

The metabolic consequences of HIV/TB co-infection

BMC Infectious Diseases, 2023
Background The synergy between the human immunodeficiency virus (HIV) and Mycobacterium tuberculosis during co-infection of a host is well known. While this synergy is known to be driven by immunological deterioration, the metabolic mechanisms that ...
Chandré Herbert, Laneke Luies, Du Toit Loots, Aurelia A. Williams   +3 more
doaj   +1 more source

HIV-1 Tat amino acid residues that influence Tat-TAR binding affinity: a scoping review

BMC Infectious Diseases, 2023
HIV-1 remains a global health concern and to date, nearly 38 million people are living with HIV. The complexity of HIV-1 pathogenesis and its subsequent prevalence is influenced by several factors including the HIV-1 subtype.
Piwai Terry Gotora, Rencia van der Sluis, Monray Edward Williams   +2 more
doaj   +1 more source

The advantages of rare disease biobanking: A localised source of genetic knowledge to benefit the South African rare disease community and related stakeholders worldwide

South African Medical Journal, 2023
-
M Dercksen, E H Conradie, C J Hendriksz, H Malherbe, B C Vorster   +4 more
doaj   +1 more source

Optimising a urinary extraction method for non-targeted GC–MS metabolomics

Scientific Reports, 2023
Urine is ideal for non-targeted metabolomics, providing valuable insights into normal and pathological cellular processes. Optimal extraction is critical since non-targeted metabolomics aims to analyse various compound classes.
Cara Olivier, Bianca Allen, Laneke Luies
doaj   +1 more source

Metabolomics in cancer research and emerging applications in clinical oncology

Ca, 2021
Cancer has myriad effects on metabolism that include both rewiring of intracellular metabolism to enable cancer cells to proliferate inappropriately and adapt to the tumor microenvironment, and changes in normal tissue metabolism.
D. R. Schmidt, R. Patel, D. Kirsch, C. Lewis, M. V. Vander Heiden, J. Locasale   +5 more
semanticscholar   +1 more source

Transcriptionally imprinted glycomic signatures of acute myeloid leukemia

Cell & Bioscience, 2023
Background Acute myeloid leukemia (AML) is a genetically and phenotypically heterogeneous disease that has been suffering from stagnant survival curves for decades.
Constantin Blöchl, Di Wang, Oleg A. Mayboroda, Guinevere S. M. Lageveen-Kammeijer, Manfred Wuhrer   +4 more
doaj   +1 more source

Toward a Standardized Strategy of Clinical Metabolomics for the Advancement of Precision Medicine [PDF]

, 2020
Despite the tremendous success, pitfalls have been observed in every step of a clinical metabolomics workflow, which impedes the internal validity of the study.
Kang, Yun Pyo, Kim, Hyung Min, Kwon, Sung Won, NGHI, TRAN, Nguyen Hoang Anh, Nguyen Phuoc Long, PARK, SANG KI   +6 more
core   +1 more source

In Silico Drug Discovery Strategies Identified ADMET Properties of Decoquinate RMB041 and Its Potential Drug Targets against Mycobacterium tuberculosis

Microbiology Spectrum, 2022
The highly adaptive cellular response of Mycobacterium tuberculosis to various antibiotics and the high costs for clinical trials, hampers the development of novel antimicrobial agents with improved efficacy and safety.
Kirsten E. Knoll, Mietha M. van der Walt, Du Toit Loots   +2 more
doaj   +1 more source